Nintedanib Teva Gmbh

Nintedanib, the active ingredient in Nintedanib Teva Gmbh, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, non‑small cell lung cancer, and systemic sclerosis‑associated interstitial lung disease in appropriate patients. The drug inhibits several receptor tyrosine kinases that drive fibroblast proliferation and angiogenesis, helping to slow disease progression.

GNH USA supplies Nintedanib Teva Gmbh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nintedanib targets multiple receptor tyrosine kinases involved in fibrosis and tumor growth, making it useful for several serious pulmonary and oncologic conditions. - Idiopathic pulmonary fibrosis: slows decline in forced vital capacity, reduces rate of disease progression, and improves quality of life in affected patients. - Non‑small cell lung cancer: used together with chemotherapy to inhibit tumor angiogenesis and proliferation, contributing to longer progression‑free survival in eligible patients. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity, delay worsening of fibrosis, and may reduce need for supplemental oxygen in this patient group.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Decreased appetite - Vomiting - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Hepatic failure or severe liver injury - Major bleeding events - Cardiovascular complications such as myocardial infarction - Gastrointestinal perforation - Severe infections or opportunistic infections

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor relevant clinical parameters. - Monitor liver function: baseline and periodic tests recommended. - Assess bleeding risk: avoid in patients with active hemorrhage. - Evaluate cardiovascular status: use caution in patients with heart disease. - Pregnancy and lactation: safety unknown, avoid unless benefits outweigh risks. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Nintedanib can interact with other medicines, requiring careful review of a patient’s medication list.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase nintedanib exposure. - Anticoagulants: heightened bleeding risk. - Concomitant use with other tyrosine kinase inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers: may reduce efficacy. - P‑glycoprotein inhibitors: may increase plasma levels. - Diuretics: monitor for dehydration and renal function.